tiprankstipranks
Advertisement
Advertisement

CTXR Stock Latest News

Citius Highlights LYMPHIR Combo Data in Gynecologic Cancers
Company AnnouncementsCitius Highlights LYMPHIR Combo Data in Gynecologic Cancers
3d ago
8K
CTXR
Citius Oncology highlights Phase 1 data evaluating Lymphir at ASCO
PremiumThe Fly
Citius Oncology highlights Phase 1 data evaluating Lymphir at ASCO
4d ago
CTOR
CTXR
CTXR, AMT, JAZZ, CTMX, FATE Trending With Analysts
PremiumWeekend Updates
CTXR, AMT, JAZZ, CTMX, FATE Trending With Analysts
13d ago
AMT
CTMX
Citius Pharmaceuticals files to sell 5.43M shares of common stock for holders
PremiumThe Fly
Citius Pharmaceuticals files to sell 5.43M shares of common stock for holders
13d ago
CTXR
Citius Pharmaceuticals assumed with a Buy at H.C. Wainwright
PremiumThe Fly
Citius Pharmaceuticals assumed with a Buy at H.C. Wainwright
18d ago
CTXR
Citius Pharmaceuticals Amends Promissory Note to Enhance Flexibility
PremiumCompany AnnouncementsCitius Pharmaceuticals Amends Promissory Note to Enhance Flexibility
27d ago
8K
CTXR
Citius Expands LYMPHIR Access with First European Shipment
Premium
Company Announcements
Citius Expands LYMPHIR Access with First European Shipment
1M ago
8K
CTXR
Citius Oncology announces initial shipment of LYMPHIR to Europe
Premium
The Fly
Citius Oncology announces initial shipment of LYMPHIR to Europe
1M ago
CTOR
CTXR
Citius Pharmaceuticals Raises $5 Million in Securities Offering
PremiumCompany Announcements
Citius Pharmaceuticals Raises $5 Million in Securities Offering
1M ago
8K
CTXR
Citius Pharmaceuticals announces $5M registered direct offering priced ATM
PremiumThe Fly
Citius Pharmaceuticals announces $5M registered direct offering priced ATM
1M ago
CTXR
Citius Pharmaceuticals Announces 2026 Annual Stockholder Meeting Results
PremiumCompany Announcements
Citius Pharmaceuticals Announces 2026 Annual Stockholder Meeting Results
2M ago
8K
CTXR
Citius Oncology advances LYMPHIR launch and global expansion
PremiumCompany Announcements
Citius Oncology advances LYMPHIR launch and global expansion
2M ago
8K
CTXR
Citius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data
PremiumCompany AnnouncementsCitius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data
3M ago
8K
CTXR
Citius Oncology Reports Positive LYMPHIR Phase 1 CAR-T Data
Premium
Company Announcements
Citius Oncology Reports Positive LYMPHIR Phase 1 CAR-T Data
3M ago
8K
CTXR
Citius Pharmaceuticals receives $3.8M through NJEDA program
Premium
The Fly
Citius Pharmaceuticals receives $3.8M through NJEDA program
3M ago
CTXR
Citius Pharmaceuticals Posts First Revenue Amid Listing Risk
PremiumCompany Announcements
Citius Pharmaceuticals Posts First Revenue Amid Listing Risk
4M ago
8K
CTXR
Citius Oncology reports Q1 EPS (6c) vs. (9c) last year
PremiumThe Fly
Citius Oncology reports Q1 EPS (6c) vs. (9c) last year
4M ago
CTOR
CTXR
Citius Pharmaceuticals reports $3.9M in revenue following launch of Lymphir
PremiumThe Fly
Citius Pharmaceuticals reports $3.9M in revenue following launch of Lymphir
4M ago
CTOR
CTXR
Citius Pharmaceuticals reports Q1 EPS (41c) vs. ($1.30) last year
PremiumThe Fly
Citius Pharmaceuticals reports Q1 EPS (41c) vs. ($1.30) last year
4M ago
CTOR
CTXR
Is CTXR a Buy, Before Earnings?
PremiumPre-EarningsIs CTXR a Buy, Before Earnings?
4M ago
CTXR
Citius Oncology to sell 1.28M shares at $1.09 in registered direct offering
Premium
The Fly
Citius Oncology to sell 1.28M shares at $1.09 in registered direct offering
6M ago
CTOR
CTXR
Citius Pharmaceuticals Launches LYMPHIR for T-Cell Lymphoma
Premium
Company Announcements
Citius Pharmaceuticals Launches LYMPHIR for T-Cell Lymphoma
6M ago
8K
CTXR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >